Iris M. Hagemans

Iris M. Hagemans

Auto-generated profile, based on publicly available information

Iris M. Hagemans

Department of Tumor Immunology and the Institute for Chemical Immunology, Radboud university medical center, Geert Grooteplein 26 , 6525 GA Nijmegen, the

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 August 2019 in Science Advances
Verified
Journal Article
Open access
PDF file
JSJohan van der Schoot
Johan van der Schoot
FFFelix L. Fennemann
Felix L. Fennemann
MVMichael Valente
Michael Valente
YDYusuf Dolen
Yusuf Dolen
IHIris M. Hagemans
Iris M. Hagemans
FSFerenc A Scheeren
Ferenc A Scheeren
We develop a universal platform for CRISPR/HDR-engineering of hybridomas to obtain functionally diverse antibody panels.

28 July 2025 in Immunotherapy Advances
Verified
Journal Article
Open access
GSGerwin G W Sandker
Gerwin G W Sandker
RRRené Raavé
René Raavé
IAInês F Antunes
Inês F Antunes
MBMilou Boswinkel
Milou Boswinkel
LCLenneke Cornelissen
Lenneke Cornelissen
SHSandra Heskamp
Sandra Heskamp
Introduction: Many immunotherapies focus on (re)invigorating CD8+ T cell anti-cancer responses. Different nuclear imaging techniques have been developed to measure CD8+ T cell distributions. Comprehensive comparisons of in vivo and ex vivo T cell labeling methods with respect to tumor and normal tissue targeting and correlation with CD8⁺ T cell presence are lacking, but essential for accurate clinical interpretation. We performed a head-to-head comparison of three CD8+ T cell imaging approaches: 89Zr-labeled Fc-silent anti-CD8 antibody ([89Zr]Zr-anti-CD8-IgG2asilent), ex vivo 89Zr-labeled ovalbumin-specific CD8+ T cells ([89Zr]Zr-OT-I), and 18F-labeled IL2 ([18F]AlF-RESCA-IL2). Methods: B16F10/OVA tumor-bearing C57BL/6 mice (n=10/group) underwent PET/CT imaging at 72 ([89Zr]Zr-anti-CD8-IgG2asilent), 24 and 48 h ([89Zr]Zr-OT-I), and 10 min ([18F]AlF-RESCA-IL2) pi. Subsequently, biodistribution analysis was performed followed by flow cytometry to evaluate intratumoral CD8+ T cell numbers. Intratumoral radiolabel distributions were assessed by autoradiography and immunohistochemistry. Results: All approaches showed uptake in CD8-rich tissues, with preferential spleen targeting. Biodistribution analyses showed tumor uptake exceeded blood level for [89Zr]Zr-anti-CD8-IgG2asilent and [89Zr]Zr-OT-I. Furthermore, their tumor uptake correlated to intratumoral CD8+ T cells presence even though intratumoral distribution patterns differed significantly. Conclusion: [89Zr]Zr-anti-CD8-IgG2asilent and [89Zr]Zr-OT-I PET/CT imaging can evaluate intratumoral CD8+ T cell infiltration. [89Zr]Zr-anti-CD8-IgG2asilent might be suited for TME immunophenotyping, while ex vivo labeling visualizes tumor migration and invasion dynamics of tumor-specific T cells. [18F]AlF-RESCA-IL2 uptake did not correlate to the intratumoral CD8+ T cell presence. Here, we provide new insights to guide the selection of imaging strategies for assessing relevant immunotherapy-specific aspects of the TME and support correct interpretation of clinical CD8 imaging.

15 October 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
GSGerwin G.W. Sandker
Gerwin G.W. Sandker
RRRené Raavé
René Raavé
IAInês F. Antunes
Inês F. Antunes
MBMilou Boswinkel
Milou Boswinkel
LCLenneke Cornelissen
Lenneke Cornelissen
SHSandra Heskamp
Sandra Heskamp
Many immunotherapies focus on (re)invigorating CD8 + T cell anti-cancer responses and different nuclear imaging techniques have been developed to measure CD8 + T cell distributions. In vivo labeling approaches using radiotracers primarily show CD8 + T cell distributions, while ex vivo labeled CD8 + T cells can show CD8 + T cell migration patterns, homing, and tumor infiltration. Currently, a comprehensive head-to-head comparison of in vivo and ex-vivo cell labeling with respect to their tumor and normal tissue targeting properties and correlation to the presence of CD8 + T cells is lacking, yet essential for correct interpretation of clinical CD8 + imaging applications. Therefore, we performed a head-to-head comparison of three different CD8 + T cell imaging approaches: 1) 89 Zr-labeled DFO-conjugated Fc-silent anti-CD8 antibody ([ 89 Zr]Zr-anti-CD8-IgG2a silent ), 2) ex vivo 89 Zr-oxine labeled ovalbumin-specific CD8 + T cells ([ 89 Zr]Zr-OT-I cells), and 3) 18 F-labeled IL2 ([ 18 F]AlF-RESCA-IL2). Methods: B16F10/OVA tumor-bearing C57BL/6 mice (n=10/group) received intravenously one of the three radiopharmaceuticals. PET/CT images were acquired starting 72 h ([ 89 Zr]Zr-anti-CD8-IgG2a silent ), 24 and 48 h ([ 89 Zr]Zr-OT-I cells), and 10 min ([ 18 F]AlF-RESCA-IL2) post injection. Subsequently, ex vivo biodistribution analysis of the radiopharmaceuticals was performed followed by flow cytometric analysis to evaluate the number of intratumoral CD8 + T cells. Additionally, the intratumoral radiolabel distributions was assessed by autoradiography and immunohistochemistry (IHC) on tumor slices. Results: [ 89 Zr]Zr-anti-CD8-IgG2a silent, [ 89 Zr]Zr-OT-I cells, and [ 18 F]AlF-RESCA-IL2 showed uptake in CD8-rich tissues, with preferential targeting to the spleen. Biodistribution analysis showed tumor uptake above blood level for all radiopharmaceuticals, except [ 18 F]AlF-RESCA-IL2. For all three approaches, the uptake in the tumor-draining lymph node was significantly higher compared with the contralateral axial lymph node, suggesting that all approaches allow evaluation of immune responses involving CD8 + T cells. Tumor uptake of [ 89 Zr]Zr-anti-CD8-IgG2a silent (R 2 =0.65, p<0.01) and [ 89 Zr]Zr-OT-I cells (R 2 =0.74, p<0.01) correlated to the number of intratumoral CD8 + T cells (flow cytometry). The intratumoral distribution pattern of the radiosignal was different for ex vivo and in vivo radiolabeling techniques. The short half-life of 18 F precluded autoradiography assessment of [ 18 F]AlF-RESCA-IL2. Conclusion: We show that [ 89 Zr]Zr-anti-CD8-IgG2a silent and [ 89 Zr]Zr-OT-I cells PET/CT imaging can be used to evaluate intratumoral CD8 + T cells, even though their normal tissues and intratumoral distribution patterns are significantly different. Based on their characteristics, [ 89 Zr]Zr-anti-CD8-IgG2a silent might be most useful to immunophenotyping the TME, while the ex vivo cell labeling approach visualizes CD8 + T cell migrations patterns and the permissiveness of tumors for invasion, whereas [ 18 F]AlF-RESCA-IL2 allows for rapid recurrent imaging and might prove useful for tracking rapid changes in CD8 + T cell distributions. In conclusion, our head-to-head comparison of the three prototype CD8 + T cell labeling approaches provides new insights which can aid in correct interpretation of clinical CD8 imaging and may guide in the selection of the optimal imaging approach for the research question of interest.